BRPI0607235A2 - mutações do receptor do fator de crescimento epidérmico - Google Patents
mutações do receptor do fator de crescimento epidérmicoInfo
- Publication number
- BRPI0607235A2 BRPI0607235A2 BRPI0607235-6A BRPI0607235A BRPI0607235A2 BR PI0607235 A2 BRPI0607235 A2 BR PI0607235A2 BR PI0607235 A BRPI0607235 A BR PI0607235A BR PI0607235 A2 BRPI0607235 A2 BR PI0607235A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutant
- egfr
- growth factor
- raf
- pi3k
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title abstract 8
- 108060006698 EGF receptor Proteins 0.000 title abstract 8
- 230000035772 mutation Effects 0.000 title abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 4
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 4
- 108091007960 PI3Ks Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 150000003905 phosphatidylinositols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65626305P | 2005-02-24 | 2005-02-24 | |
| PCT/US2006/006751 WO2006091899A2 (en) | 2005-02-24 | 2006-02-23 | Epidermal growth factor receptor mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607235A2 true BRPI0607235A2 (pt) | 2009-08-25 |
Family
ID=36579263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607235-6A BRPI0607235A2 (pt) | 2005-02-24 | 2006-02-23 | mutações do receptor do fator de crescimento epidérmico |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7981605B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1851243A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008535477A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070106029A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101208354A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2006216477A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0607235A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2601936C (cg-RX-API-DMAC7.html) |
| CR (1) | CR9390A (cg-RX-API-DMAC7.html) |
| EA (1) | EA013617B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL185210A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007009963A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20074826L (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006091899A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200707379B (cg-RX-API-DMAC7.html) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
| CA2597673C (en) | 2005-02-11 | 2014-07-08 | Harold Varmus | Methods and compositions for detecting a drug resistant egfr mutant |
| US12366585B2 (en) | 2006-05-18 | 2025-07-22 | Caris Mpi, Inc. | Molecular profiling of tumors |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| AU2008221118B2 (en) | 2007-03-01 | 2013-10-03 | Les Laboratoires Servier | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US9340601B2 (en) | 2007-03-01 | 2016-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Splice variants of the EGF receptor |
| PE20090690A1 (es) | 2007-03-13 | 2009-06-22 | Amgen Inc | Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| TW201002346A (en) * | 2008-04-11 | 2010-01-16 | Galaxy Biotech Llc | Combination of HGF inhibitor and EGF inhibitor to treat cancer |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP2313758B1 (en) * | 2008-07-17 | 2012-02-01 | Koninklijke Philips Electronics N.V. | Nanopore device and a method for nucleic acid analysis |
| US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| EP3722810A3 (en) * | 2009-02-11 | 2021-01-13 | Caris MPI, Inc. | Molecular profiling of tumors |
| US8623604B2 (en) * | 2009-09-09 | 2014-01-07 | Quintiles Transnational Corp. | Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA |
| CA2803571C (en) * | 2010-07-07 | 2017-10-24 | Eisai R&D Management Co., Ltd. | Method for producing tumor cells from normal mammary epithelial cells |
| US20120164641A1 (en) * | 2010-12-22 | 2012-06-28 | Roche Molecular Systems, Inc. | Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene |
| CN103619881B (zh) | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | 新的egfr结合蛋白 |
| WO2012154908A2 (en) * | 2011-05-10 | 2012-11-15 | Brunangelo Falini | Hairy cell leukemia biomarkers and methods of using same |
| EP2554551A1 (en) * | 2011-08-03 | 2013-02-06 | Fundacio Institut mar d'Investigacions Médiques (IMIM) | Mutations in the epidermal growth factor receptor gene |
| US20140005119A1 (en) * | 2012-06-28 | 2014-01-02 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS |
| JP6574136B2 (ja) * | 2013-01-14 | 2019-09-18 | ナショナル タイワン ユニバーシティ | Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム |
| CN103739713B (zh) * | 2013-12-10 | 2016-03-09 | 吴炯 | 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用 |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| GB2521355A (en) * | 2013-12-17 | 2015-06-24 | Kymab Ltd | Human targets I |
| WO2015092394A1 (en) * | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US9980967B1 (en) | 2017-03-16 | 2018-05-29 | National Chiao Tung University | Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma |
| CN108047308A (zh) * | 2018-02-02 | 2018-05-18 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108047309A (zh) * | 2018-02-07 | 2018-05-18 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108250268A (zh) * | 2018-02-08 | 2018-07-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108218959A (zh) * | 2018-03-07 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108218960A (zh) * | 2018-03-07 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108409832A (zh) * | 2018-03-07 | 2018-08-17 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108218961A (zh) * | 2018-03-19 | 2018-06-29 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440649A (zh) * | 2018-05-31 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108752424A (zh) * | 2018-06-04 | 2018-11-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440650A (zh) * | 2018-06-04 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440651A (zh) * | 2018-06-08 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| WO2020024976A1 (en) * | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof |
| CN109485721A (zh) * | 2018-11-23 | 2019-03-19 | 杜学明 | 一种获得肿瘤特异性t细胞受体的方法 |
| RU2706116C1 (ru) * | 2018-12-26 | 2019-11-14 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ прогнозирования течения аденокарциномы легкого |
| WO2020145711A1 (ko) * | 2019-01-11 | 2020-07-16 | 주식회사 진캐스트 | Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 |
| WO2020145754A1 (ko) * | 2019-01-11 | 2020-07-16 | 주식회사 진캐스트 | 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법 |
| KR102310819B1 (ko) * | 2019-01-11 | 2021-10-12 | 주식회사 진캐스트 | Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 |
| WO2020174370A2 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| CN113993544A (zh) * | 2019-07-24 | 2022-01-28 | 神州细胞工程有限公司 | 用于治疗egfr高表达的癌症的多变剂量方法 |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| AU639726B2 (en) * | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| US20010046686A1 (en) * | 2000-03-10 | 2001-11-29 | Wong Albert J. | Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample |
| US20050277118A1 (en) * | 2002-09-11 | 2005-12-15 | Roth Richard B | Methods for identifying subjects at risk of melanoma and treatments thereof |
| ES2741546T3 (es) * | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
| EP3042964A1 (en) * | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| KR20150140417A (ko) * | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US7442507B2 (en) * | 2005-01-24 | 2008-10-28 | New York University School Of Medicine | Methods for detecting circulating mutant BRAF DNA |
| EP1877379B1 (en) * | 2005-04-13 | 2013-01-16 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
| JP2008546421A (ja) | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Ｅｇｆｒおよびｋｒａｓ変異 |
-
2006
- 2006-02-23 US US11/361,711 patent/US7981605B2/en active Active
- 2006-02-23 BR BRPI0607235-6A patent/BRPI0607235A2/pt not_active IP Right Cessation
- 2006-02-23 WO PCT/US2006/006751 patent/WO2006091899A2/en not_active Ceased
- 2006-02-23 JP JP2007557212A patent/JP2008535477A/ja active Pending
- 2006-02-23 AU AU2006216477A patent/AU2006216477A1/en not_active Abandoned
- 2006-02-23 MX MX2007009963A patent/MX2007009963A/es not_active Application Discontinuation
- 2006-02-23 EA EA200701804A patent/EA013617B1/ru not_active IP Right Cessation
- 2006-02-23 CN CNA2006800138392A patent/CN101208354A/zh active Pending
- 2006-02-23 CA CA2601936A patent/CA2601936C/en active Active
- 2006-02-23 EP EP06721064A patent/EP1851243A2/en not_active Ceased
- 2006-02-23 KR KR1020077021517A patent/KR20070106029A/ko not_active Withdrawn
-
2007
- 2007-08-12 IL IL185210A patent/IL185210A0/en unknown
- 2007-08-30 ZA ZA200707379A patent/ZA200707379B/xx unknown
- 2007-09-21 NO NO20074826A patent/NO20074826L/no not_active Application Discontinuation
- 2007-09-24 CR CR9390A patent/CR9390A/es unknown
-
2010
- 2010-11-15 AU AU2010241462A patent/AU2010241462A1/en not_active Abandoned
-
2011
- 2011-07-15 US US13/184,474 patent/US8546107B2/en active Active
-
2012
- 2012-03-06 JP JP2012049012A patent/JP2012149070A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA200701804A1 (ru) | 2008-06-30 |
| NO20074826L (no) | 2007-11-23 |
| EP1851243A2 (en) | 2007-11-07 |
| CA2601936C (en) | 2014-06-17 |
| US7981605B2 (en) | 2011-07-19 |
| IL185210A0 (en) | 2008-01-06 |
| US20120328620A1 (en) | 2012-12-27 |
| KR20070106029A (ko) | 2007-10-31 |
| CR9390A (es) | 2008-01-02 |
| AU2010241462A1 (en) | 2010-12-16 |
| US8546107B2 (en) | 2013-10-01 |
| ZA200707379B (en) | 2008-10-29 |
| EA013617B1 (ru) | 2010-06-30 |
| JP2012149070A (ja) | 2012-08-09 |
| AU2006216477A1 (en) | 2006-08-31 |
| JP2008535477A (ja) | 2008-09-04 |
| CA2601936A1 (en) | 2006-08-31 |
| CN101208354A (zh) | 2008-06-25 |
| WO2006091899A2 (en) | 2006-08-31 |
| MX2007009963A (es) | 2007-09-26 |
| WO2006091899A3 (en) | 2007-02-22 |
| US20070048754A1 (en) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607235A2 (pt) | mutações do receptor do fator de crescimento epidérmico | |
| MX2013004305A (es) | Metodos para determinar isotipos de anticuerpos anti-farmacos. | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| MX2019005150A (es) | Inhibidores de la tirosina-cinasa de bruton. | |
| BR112013005958A2 (pt) | "mistura de fluxo de áudio com normalização do nível de diálogo". | |
| Sener et al. | T helper cell activation and expansion is sensitive to glutaminase inhibition under both hypoxic and normoxic conditions | |
| MA33256B1 (fr) | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation | |
| WO2010033866A3 (en) | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma | |
| DK1842226T3 (da) | Homogen analytpåvisning | |
| Won et al. | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients | |
| EP1912674A4 (en) | BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF | |
| NZ602840A (en) | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor | |
| NO20043245L (no) | Bindingsproteiner som biosensorer | |
| MX2007003522A (es) | Complicaciones del embarazo. | |
| BRPI0413466A (pt) | anticorpos igf-1r humanos modificados | |
| FR2933773B1 (fr) | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal | |
| EP2274437A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING EGFR MUTATIONS IN CANCER | |
| WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
| Niehage et al. | Cell surface proteome of dental pulp stem cells identified by label-free mass spectrometry | |
| SG155931A1 (en) | Wnt proteins and detection and treatment of cancer | |
| Hartmann et al. | Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab | |
| Ziegler et al. | Proteomic surfaceome analysis of mesothelioma | |
| Awasthi et al. | Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma | |
| WO2011159741A3 (en) | Tetranor-pgem/pgam specific immunogens, antibodies, tracers, assay kits and methods for making same | |
| WO2017030506A1 (en) | Method for detecting circulating tumor cells and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |